[{"id":"e3b4bad8-8656-47cc-998e-a5d2146657b6","acronym":"ALCHEMIST Screening","url":"https://clinicaltrials.gov/study/NCT02194738","created_at":"2021-01-18T10:15:39.910Z","updated_at":"2025-02-25T12:26:10.714Z","phase":"","brief_title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","source_id_and_acronym":"NCT02194738 - ALCHEMIST Screening","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • gemcitabine • paclitaxel • docetaxel • Mektovi (binimetinib) • pemetrexed • sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 8300","initiation":"Initiation: 09/26/2014","start_date":" 09/26/2014","primary_txt":" Primary completion: 09/28/2026","primary_completion_date":" 09/28/2026","study_txt":" Completion: 09/28/2026","study_completion_date":" 09/28/2026","last_update_posted":"2025-02-24"},{"id":"111dadaf-4e0e-41c4-96f3-ff25aabf637a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03047213","created_at":"2021-01-18T15:00:26.479Z","updated_at":"2025-02-25T15:17:24.811Z","phase":"Phase 2","brief_title":"Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations","source_id_and_acronym":"NCT03047213","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TSC2 • TSC1","pipe":" | ","alterations":" TSC1 mutation • TSC2 mutation","tags":["TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TSC1 mutation • TSC2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 08/24/2017","start_date":" 08/24/2017","primary_txt":" Primary completion: 10/06/2020","primary_completion_date":" 10/06/2020","study_txt":" Completion: 11/11/2025","study_completion_date":" 11/11/2025","last_update_posted":"2025-02-12"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"08e8d834-7d1c-43f8-b2b4-1023ee00f03e","acronym":"X31025","url":"https://clinicaltrials.gov/study/NCT03154294","created_at":"2025-09-13T10:56:31.458Z","updated_at":"2025-09-13T10:56:31.458Z","phase":"Phase 1","brief_title":"Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors","source_id_and_acronym":"NCT03154294 - X31025","lead_sponsor":"Avera McKennan Hospital \u0026 University Health Center","biomarkers":" PI3K","pipe":"","alterations":" ","tags":["PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • sapanisertib (CB-228) • serabelisib (MLN1117)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 07/06/2017","start_date":" 07/06/2017","primary_txt":" Primary completion: 11/20/2020","primary_completion_date":" 11/20/2020","study_txt":" Completion: 11/20/2022","study_completion_date":" 11/20/2022","last_update_posted":"2024-07-26"},{"id":"92435528-4415-4d93-8e63-2a53a10bdf30","acronym":"","url":"https://clinicaltrials.gov/study/NCT04250545","created_at":"2021-01-18T20:39:21.304Z","updated_at":"2024-07-02T16:34:58.880Z","phase":"Phase 1","brief_title":"Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04250545","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • ALK • ROS1 • KEAP1 • NFE2L2","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • BRAF V600K • KEAP1 mutation • NFE2L2 mutation","tags":["KRAS • BRAF • ALK • ROS1 • KEAP1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • BRAF V600K • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228) • telaglenastat (CB-839)"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 10/26/2020","start_date":" 10/26/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"c4a67b85-d57e-45f1-9a88-e437704888be","acronym":"","url":"https://clinicaltrials.gov/study/NCT04479306","created_at":"2021-01-18T21:30:41.583Z","updated_at":"2024-07-02T16:34:59.204Z","phase":"Phase 1","brief_title":"Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04479306","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L858R + EGFR exon 21 deletion","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L858R + EGFR exon 21 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • sapanisertib (CB-228) • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 06/18/2020","start_date":" 06/18/2020","primary_txt":" Primary completion: 07/27/2023","primary_completion_date":" 07/27/2023","study_txt":" Completion: 07/27/2023","study_completion_date":" 07/27/2023","last_update_posted":"2024-06-04"},{"id":"c81f4907-3d78-44bf-bbba-6db76728d952","acronym":"","url":"https://clinicaltrials.gov/study/NCT02484430","created_at":"2021-01-29T07:10:20.095Z","updated_at":"2024-07-02T16:35:04.995Z","phase":"Phase 2","brief_title":"Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02484430","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 10/20/2016","start_date":" 10/20/2016","primary_txt":" Primary completion: 12/28/2018","primary_completion_date":" 12/28/2018","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-05-08"},{"id":"653b0929-1d57-4b2a-adf0-7e0b59367122","acronym":"","url":"https://clinicaltrials.gov/study/NCT02142803","created_at":"2021-01-18T09:57:08.346Z","updated_at":"2024-07-02T16:35:16.708Z","phase":"Phase 1","brief_title":"TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors","source_id_and_acronym":"NCT02142803","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • sapanisertib (CB-228) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/20/2014","start_date":" 05/20/2014","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-03-01"},{"id":"a49319c7-fc86-477e-9d18-340184f8a72b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03193853","created_at":"2021-01-18T15:44:59.657Z","updated_at":"2025-02-25T14:50:33.000Z","phase":"Phase 2","brief_title":"TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03193853","lead_sponsor":"Joyce O'Shaughnessy","biomarkers":" AR","pipe":" | ","alterations":" AR negative","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • albumin-bound paclitaxel • sapanisertib (CB-228) • serabelisib (MLN1117)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 07/18/2017","start_date":" 07/18/2017","primary_txt":" Primary completion: 03/17/2020","primary_completion_date":" 03/17/2020","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2023-08-07"},{"id":"4e6878e9-d76c-4e3d-9894-9e482c8740b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02049957","created_at":"2021-01-18T09:25:38.733Z","updated_at":"2024-07-02T16:35:56.099Z","phase":"Phase 1b/2","brief_title":"Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer","source_id_and_acronym":"NCT02049957","lead_sponsor":"Calithera Biosciences, Inc","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • fulvestrant • sapanisertib (CB-228) • exemestane"],"overall_status":"Completed","enrollment":" Enrollment 118","initiation":"Initiation: 02/13/2014","start_date":" 02/13/2014","primary_txt":" Primary completion: 06/29/2018","primary_completion_date":" 06/29/2018","study_txt":" Completion: 06/29/2018","study_completion_date":" 06/29/2018","last_update_posted":"2023-02-08"},{"id":"a517e148-0243-41aa-abf4-ba369a1377ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT02756364","created_at":"2021-01-17T17:33:46.971Z","updated_at":"2024-07-02T16:35:56.110Z","phase":"Phase 2","brief_title":"Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy","source_id_and_acronym":"NCT02756364","lead_sponsor":"Calithera Biosciences, Inc","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • sapanisertib (CB-228)"],"overall_status":"Completed","enrollment":" Enrollment 141","initiation":"Initiation: 07/28/2016","start_date":" 07/28/2016","primary_txt":" Primary completion: 11/25/2019","primary_completion_date":" 11/25/2019","study_txt":" Completion: 11/25/2019","study_completion_date":" 11/25/2019","last_update_posted":"2023-02-08"},{"id":"4af2b883-4b5c-4b1a-b8a8-6f3373185c01","acronym":"","url":"https://clinicaltrials.gov/study/NCT02719691","created_at":"2021-01-18T13:18:17.871Z","updated_at":"2024-07-02T16:36:06.763Z","phase":"Phase 1","brief_title":"Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer","source_id_and_acronym":"NCT02719691","lead_sponsor":"University of Colorado, Denver","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228) • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 05/13/2016","start_date":" 05/13/2016","primary_txt":" Primary completion: 03/18/2020","primary_completion_date":" 03/18/2020","study_txt":" Completion: 03/18/2020","study_completion_date":" 03/18/2020","last_update_posted":"2022-07-25"},{"id":"8ae6d248-ecbb-408f-8f2f-48c143b00eec","acronym":"","url":"https://clinicaltrials.gov/study/NCT02417701","created_at":"2021-01-17T17:54:54.823Z","updated_at":"2024-07-02T16:36:13.984Z","phase":"Phase 2","brief_title":"Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer","source_id_and_acronym":"NCT02417701","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • KEAP1 • NFE2L2 • CD4","pipe":" | ","alterations":" KRAS mutation • KEAP1 mutation • NFE2L2 mutation","tags":["KRAS • KEAP1 • NFE2L2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 10/06/2016","start_date":" 10/06/2016","primary_txt":" Primary completion: 12/28/2020","primary_completion_date":" 12/28/2020","study_txt":" Completion: 12/28/2020","study_completion_date":" 12/28/2020","last_update_posted":"2022-04-05"},{"id":"3050983b-af30-46fd-910e-e5f5087885ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT02724020","created_at":"2021-01-18T13:19:55.870Z","updated_at":"2024-07-02T16:36:20.474Z","phase":"Phase 2","brief_title":"MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma","source_id_and_acronym":"NCT02724020","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • sapanisertib (CB-228) • serabelisib (MLN1117)"],"overall_status":"Completed","enrollment":" Enrollment 96","initiation":"Initiation: 06/30/2016","start_date":" 06/30/2016","primary_txt":" Primary completion: 02/03/2020","primary_completion_date":" 02/03/2020","study_txt":" Completion: 10/13/2020","study_completion_date":" 10/13/2020","last_update_posted":"2021-11-19"},{"id":"117e7c26-f674-404d-a2a1-b4771e7bb528","acronym":"ANETT","url":"https://clinicaltrials.gov/study/NCT02988986","created_at":"2021-01-18T14:42:11.237Z","updated_at":"2025-02-25T14:50:23.622Z","phase":"Phase 2","brief_title":"TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer","source_id_and_acronym":"NCT02988986 - ANETT","lead_sponsor":"The Methodist Hospital Research Institute","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • sapanisertib (CB-228)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 04/24/2017","start_date":" 04/24/2017","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":" Completion: 03/30/2019","study_completion_date":" 03/30/2019","last_update_posted":"2021-09-22"},{"id":"2d1fef42-d797-428a-8f56-db28088ee549","acronym":"ECOG-ACRIN LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT04267913","created_at":"2021-01-18T20:44:15.415Z","updated_at":"2024-07-02T16:36:38.345Z","phase":"Phase 2","brief_title":"Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT04267913 - ECOG-ACRIN LUNG-MAP Sub-Study","lead_sponsor":"Southwest Oncology Group","biomarkers":" KEAP1 • NFE2L2 • CD4","pipe":" | ","alterations":" KEAP1 mutation • NFE2L2 mutation","tags":["KEAP1 • NFE2L2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Cyramza (ramucirumab) • sapanisertib (CB-228) • dexamethasone injection • lexatumumab (ETR2-ST01)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/05/2020","start_date":" 09/05/2020","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2020-11-20"},{"id":"d2d91677-fe2c-4e79-b8f3-95798ef44dd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01058707","created_at":"2021-01-18T04:10:10.019Z","updated_at":"2024-07-02T16:36:47.003Z","phase":"Phase 1","brief_title":"Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies","source_id_and_acronym":"NCT01058707","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" EIF4EBP1 • RPS6","pipe":"","alterations":" ","tags":["EIF4EBP1 • RPS6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228)"],"overall_status":"Completed","enrollment":" Enrollment 198","initiation":"Initiation: 01/04/2010","start_date":" 01/04/2010","primary_txt":" Primary completion: 02/07/2019","primary_completion_date":" 02/07/2019","study_txt":" Completion: 02/07/2019","study_completion_date":" 02/07/2019","last_update_posted":"2020-04-01"},{"id":"5dcf4fac-10ec-4bc6-a9e8-3fc7629b898a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02619669","created_at":"2021-01-18T12:43:39.062Z","updated_at":"2024-07-02T16:36:48.726Z","phase":"Phase 1b","brief_title":"Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer","source_id_and_acronym":"NCT02619669","lead_sponsor":"Gary Schwartz","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • sapanisertib (CB-228) • sirolimus"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/20/2017","start_date":" 04/20/2017","primary_txt":" Primary completion: 06/14/2019","primary_completion_date":" 06/14/2019","study_txt":" Completion: 06/14/2019","study_completion_date":" 06/14/2019","last_update_posted":"2020-03-12"},{"id":"bb4a6aa4-08e9-4d44-bc20-09c982a16bd2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02327169","created_at":"2021-01-18T11:02:33.167Z","updated_at":"2024-07-02T16:36:49.576Z","phase":"Phase 1b","brief_title":"A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies","source_id_and_acronym":"NCT02327169","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF mutation • KRAS exon 2 mutation","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • paclitaxel • irinotecan • sapanisertib (CB-228) • Ojemda (tovorafenib) • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 01/14/2015","start_date":" 01/14/2015","primary_txt":" Primary completion: 07/02/2018","primary_completion_date":" 07/02/2018","study_txt":" Completion: 07/02/2018","study_completion_date":" 07/02/2018","last_update_posted":"2020-02-25"},{"id":"5314ed0d-634b-4fc9-aff7-4f00cb64cfff","acronym":"","url":"https://clinicaltrials.gov/study/NCT01351350","created_at":"2021-01-18T05:31:20.599Z","updated_at":"2024-07-02T16:36:57.137Z","phase":"Phase 1","brief_title":"Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies","source_id_and_acronym":"NCT01351350","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • sapanisertib (CB-228)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 02/28/2011","start_date":" 02/28/2011","primary_txt":" Primary completion: 09/15/2017","primary_completion_date":" 09/15/2017","study_txt":" Completion: 09/15/2017","study_completion_date":" 09/15/2017","last_update_posted":"2019-08-08"},{"id":"956a6940-1807-42e7-b62a-6ba5b99d5c2b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03205891","created_at":"2021-01-18T15:48:03.787Z","updated_at":"2025-02-25T14:50:33.845Z","phase":"Phase 1","brief_title":"Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas","source_id_and_acronym":"NCT03205891","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin) • sapanisertib (CB-228)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 03/01/2021","study_completion_date":" 03/01/2021","last_update_posted":"2018-01-17"},{"id":"4e9ede92-6285-4b0b-b009-176ccbfbc39c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03108261","created_at":"2021-01-18T15:18:47.515Z","updated_at":"2024-07-02T16:37:16.148Z","phase":"Phase 2","brief_title":"Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations","source_id_and_acronym":"NCT03108261","lead_sponsor":"Yale University","biomarkers":" TSC2 • TSC1","pipe":" | ","alterations":" TSC1 mutation • TSC2 mutation","tags":["TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TSC1 mutation • TSC2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 209","initiation":"Initiation: 05/01/2017","start_date":" 05/01/2017","primary_txt":" Primary completion: 12/31/2018","primary_completion_date":" 12/31/2018","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2017-11-21"}]